연구동향 분석
박사

GITR 자극을 통한 항암 면역 치료의 작용 기전에 대한 연구 : Studies on the mechanism of GITR-modulating antitumor immunotherapy

김일규 2015년

논문상세정보
인용/피인용
' GITR 자극을 통한 항암 면역 치료의 작용 기전에 대한 연구 : Studies on the mechanism of GITR-modulating antitumor immunotherapy' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • antitumor immunotherapy
  • gitr
  • il-9
  • th9
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
12 0

0.0%

' GITR 자극을 통한 항암 면역 치료의 작용 기전에 대한 연구 : Studies on the mechanism of GITR-modulating antitumor immunotherapy' 의 참고문헌

  • van der Werf, N. et al. Th2 responses to helminth parasites can betherapeutically enhanced by, but are not dependent upon, GITR-GITR ligandcostimulation in vivo. J Immunol 187, 1411-20 (2011).
  • Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nat RevImmunol 6, 295-307 (2006).67
  • Zhu, J., Yamane, H. & Paul, W.E. Differentiation of effector CD4 T cellpopulations. Annu Rev Immunol 28, 445-89 (2010).
  • Zhou, P., L'Italien, L., Hodges, D. & Schebye, X.M. Pivotal roles of CD4+effector T cells in mediating agonistic anti-GITR mAb-induced-immuneactivation and tumor immunity in CT26 tumors. J Immunol 179, 7365-75(2007).
  • Zhou, P. et al. Mature B cells are critical to T-cell-mediated tumor immunityinduced by an agonist anti-GITR monoclonal antibody. J Immunother 33,789-97 (2010).
  • Yao, W. et al. Interleukin-9 is required for allergic airway inflammationmediated by the cytokine TSLP. Immunity 38, 360-72 (2013).
  • Xiao, X. et al. OX40 signaling favors the induction of T(H)9 cells and airwayinflammation. Nat Immunol 13, 981-90 (2012).
  • Wilhelm, C. et al. An IL-9 fate reporter demonstrates the induction of aninnate IL-9 response in lung inflammation. Nat Immunol 12, 1071-7 (2011).
  • Wang, L. et al. IL-17 can promote tumor growth through an IL-6-Stat3signaling pathway. J Exp Med 206, 1457-64 (2009).
  • Veldhoen, M. et al. Transforming growth factor-beta 'reprograms' thedifferentiation of T helper 2 cells and promotes an interleukin 9-producingsubset. Nat Immunol 9, 1341-6 (2008).
  • Vanneman, M. & Dranoff, G. Combining immunotherapy and targetedtherapies in cancer treatment. Nat Rev Cancer 12, 237-51 (2012).
  • Topalian, S.L., Drake, C.G. & Pardoll, D.M. Targeting the PD-1/B7-H1(PDL1)pathway to activate anti-tumor immunity. Curr Opin Immunol 24, 207-12(2012).
  • Tone, M. et al. Mouse glucocorticoid-induced tumor necrosis factor receptorligand is costimulatory for T cells. Proc Natl Acad Sci U S A 100, 15059-64(2003).65
  • Takami, M., Love, R.B. & Iwashima, M. TGF-beta converts apoptotic stimuliinto the signal for Th9 differentiation. J Immunol 188, 4369-75 (2012).
  • Staudt, V. et al. Interferon-regulatory factor 4 is essential for thedevelopmental program of T helper 9 cells. Immunity 33, 192-202 (2010).
  • Stassen, M. et al. IL-9 and IL-13 production by activated mast cells isstrongly enhanced in the presence of lipopolysaccharide: NF-kappa B isdecisively involved in the expression of IL-9. J Immunol 166, 4391-8 (2001).
  • Schaer, D.A., Murphy, J.T. & Wolchok, J.D. Modulation of GITR for cancerimmunotherapy. Curr Opin Immunol 24, 217-24 (2012).
  • Ruffell, B., Affara, N.I. & Coussens, L.M. Differential macrophageprogramming in the tumor microenvironment. Trends Immunol 33, 119-26(2012).
  • Ramirez-Montagut, T. et al. Glucocorticoid-induced TNF receptor familyrelated gene activation overcomes tolerance/ignorance to melanomadifferentiation antigens and enhances antitumor immunity. J Immunol 176,6434-42 (2006).
  • Purwar, R. et al. Robust tumor immunity to melanoma mediated byinterleukin-9-producing T cells. Nat Med 18, 1248-53 (2012).
  • Perumal, N.B. & Kaplan, M.H. Regulating Il9 transcription in T helper cells.Trends Immunol 32, 146-50 (2011).68
  • Peggs, K.S., Quezada, S.A., Korman, A.J. & Allison, J.P. Principles and useof anti-CTLA4 antibody in human cancer immunotherapy. Curr OpinImmunol 18, 206-13 (2006).
  • Patel, M. et al. Glucocorticoid-induced TNFR family-related protein (GITR)activation exacerbates murine asthma and collagen-induced arthritis. Eur JImmunol 35, 3581-90 (2005).
  • Nishikawa, H. et al. Regulatory T cell-resistant CD8+ T cells induced byglucocorticoid-induced tumor necrosis factor receptor signaling. Cancer Res68, 5948-54 (2008).
  • Muranski, P. et al. Tumor-specific Th17-polarized cells eradicate largeestablished melanoma. Blood 112, 362-73 (2008).
  • Muranski, P. & Restifo, N.P. Adoptive immunotherapy of cancer usingCD4(+) T cells. Curr Opin Immunol 21, 200-8 (2009).
  • Motta, A.C. et al. GITR signaling potentiates airway hyperresponsiveness byenhancing Th2 cell activity in a mouse model of asthma. Respir Res 10, 93(2009).
  • Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D.M. & Chen, L.Immunostimulatory monoclonal antibodies for cancer therapy. Nat RevCancer 7, 95-106 (2007).
  • Mattes, J. et al. Immunotherapy of cytotoxic T cell-resistant tumors by T71helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med 197,387-93 (2003).
  • Martin-Orozco, N. et al. T helper 17 cells promote cytotoxic T cell activationin tumor immunity. Immunity 31, 787-98 (2009).
  • Maio, M., Di Giacomo, A.M., Robert, C. & Eggermont, A.M. Update on therole of ipilimumab in melanoma and first data on new combination therapies.Curr Opin Oncol 25, 166-72 (2013).
  • Lu, Y. et al. Th9 cells promote antitumor immune responses in vivo. J ClinInvest 122, 4160-71 (2012).
  • Lin, G.H., Snell, L.M., Wortzman, M.E., Clouthier, D.L. & Watts, T.H. GITRdependentregulation of 4-1BB expression: implications for T cell memoryand anti-4-1BB-induced pathology. J Immunol 190, 4627-39 (2013).
  • Licona-Limon, P. et al. Th9 Cells Drive Host Immunity againstGastrointestinal Worm Infection. Immunity 39, 744-57 (2013).
  • Ko, K. et al. Treatment of advanced tumors with agonistic anti-GITR mAb66and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. JExp Med 202, 885-91 (2005).
  • Kitajima, M. et al. Memory type 2 helper T cells induce long-lastingantitumor immunity by activating natural killer cells. Cancer Res 71, 4790-8(2011).
  • King, C.G. et al. TRAF6 is a T cell-intrinsic negative regulator required forthe maintenance of immune homeostasis. Nat Med 12, 1088-92 (2006).
  • Kim, W.J. et al. Glucocorticoid-induced tumour necrosis factor receptor69family related protein (GITR) mediates inflammatory activation ofmacrophages that can destabilize atherosclerotic plaques. Immunology 119,421-9 (2006).
  • Kennedy, R. & Celis, E. Multiple roles for CD4+ T cells in anti-tumorimmune responses. Immunol Rev 222, 129-44 (2008).
  • Kaplan, M.H. Th9 cells: differentiation and disease. Immunol Rev 252, 104-15 (2013).
  • Jash, A. et al. Nuclear factor of activated T cells 1 (NFAT1)-inducedpermissive chromatin modification facilitates nuclear factor-kappaB (NFkappaB)-mediated interleukin-9 (IL-9) transactivation. J Biol Chem 287,15445-57 (2012).
  • Jabeen, R. et al. Th9 cell development requires a BATF-regulatedtranscriptional network. J Clin Invest 123, 4641-53 (2013).
  • Hung, K. et al. The central role of CD4(+) T cells in the antitumor immuneresponse. J Exp Med 188, 2357-68 (1998).
  • Hong, S. et al. Roles of idiotype-specific t cells in myeloma cell growth andsurvival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumorgrowth. Cancer Res 68, 8456-64 (2008).
  • Haribhai, D. et al. Regulatory T cells dynamically control the primaryimmune response to foreign antigen. J Immunol 178, 2961-72 (2007).
  • Ephrem, A. et al. Modulation of Treg cells/T effector function by GITRsignaling is context-dependent. Eur J Immunol 43, 2421-9 (2013).
  • Elyaman, W. et al. Notch receptors and Smad3 signaling cooperate in theinduction of interleukin-9-producing T cells. Immunity 36, 623-34 (2012).
  • Dunn, G.P., Koebel, C.M. & Schreiber, R.D. Interferons, immunity and cancerimmunoediting. Nat Rev Immunol 6, 836-48 (2006).
  • De Monte, L. et al. Intratumor T helper type 2 cell infiltrate correlates withcancer-associated fibroblast thymic stromal lymphopoietin production andreduced survival in pancreatic cancer. J Exp Med 208, 469-78 (2011).
  • Dardalhon, V. et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and,together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells.70Nat Immunol 9, 1347-55 (2008).
  • Croft, M. Co-stimulatory members of the TNFR family: keys to effective Tcellimmunity? Nat Rev Immunol 3, 609-20 (2003).
  • Cohen, A.D. et al. Agonist anti-GITR monoclonal antibody inducesmelanoma tumor immunity in mice by altering regulatory T cell stability andintra-tumor accumulation. PLoS One 5, e10436 (2010).
  • Chang, H.C. et al. The transcription factor PU.1 is required for thedevelopment of IL-9-producing T cells and allergic inflammation. NatImmunol 11, 527-34 (2010).
  • Angkasekwinai, P., Chang, S.H., Thapa, M., Watarai, H. & Dong, C.Regulation of IL-9 expression by IL-25 signaling. Nat Immunol 11, 250-6(2010).